Navigation Links
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Date:6/29/2009

dwide patent applications held by or exclusively licensed to DOR, orBec(R) also benefits from orphan drug designations in the US and in Europe for the treatment of GI GVHD, which provide for seven and 10 years of post-approval market exclusivity, respectively. DOR is also continuing to actively build intellectual property around oral BDP in other inflammatory conditions.

About DOR BioPharma, Inc.

DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clinical trial of DOR201 in acute radiation enteritis in the second half of 2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Oral BDP may also have application in treating other gastrointestinal disorders characterized by severe inflammation. Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin, botulinum toxin and anthrax. DOR's ricin toxin vaccine, RiVax(TM), has been shown to be well tolerated and immunogenic in
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Patheon Inc ., a leading ... global pharmaceutical industry, will host a complimentary webinar on ... on Tuesday, June 4, 2013 at 11 a.m. Eastern ... to comply with regulations for cleaning validation. Many ... underpinning and little evaluation of risk. Some companies ...
(Date:5/23/2013)... 23, 2013 The maker community is ... of inventions. They focus on learning practical skills while ... gravitate toward bringing their ideas to life via crowdfunding. ... works on making projects using biology. Glowing Plant has ... to make them glow with bioluminescence genes, and has ...
(Date:5/23/2013)... , May 23, 2013  Saddleback Memorial Medical ... recently became the first hospital on the West Coast ... This new surgical option provides women with a state-of-the-art, ... Marc Winter , M.D., a highly ... surgeon and medical director of minimally invasive surgery at ...
(Date:5/23/2013)... May 23, 2013 On April 19th ... to supermarkets to search for the growing antibiotic resistant ... Results from a year long study were released late ... foods, specifically meats, over previous years. For those suffering ... growth of antibiotic resistant bacteria in food, may eventually ...
Breaking Biology Technology:Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2
... Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) today announced ... of,the inaugural companies in the new NASDAQ(R) NeuroInsights(R) ... an index designed to track,the performance of selected ... three major U.S. stock exchanges. The NASDAQ NeuroInsights,Neurotech ...
... MacroGenics, Inc. announced,today that Mr. Jeffrey H. Buchalter ... of Directors. With more than 20 years of ... and,biotechnology industry, Mr. Buchalter is well poised to ... company matures toward,commercializing its pipeline. "We are ...
... York, September 26 XTL,Biopharmaceuticals Ltd. (NASDAQ: ... on September 24, 2007, the Company received a ... comply with the minimum,$10 million shareholders, equity requirement ... set forth in Marketplace Rule 4450(a)(3), and that,its ...
Cached Biology Technology:Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 3Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 2Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman 3XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 2XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market 3
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
(Date:5/22/2013)... 22, 2013 U.S. Forest Service scientists are part ... funding from the TKF Foundation, will examine how collaborative ... individuals recover from tragedy. , The TKF Foundation announced ... projects selected for grant funding. In addition to research ... in recovery and resiliency, the 3-year, $585,000 grant will ...
(Date:5/22/2013)... developed a novel technique that can detect molecular variants ... is one of the most important, though time-consuming, processes ... paper in Nature , post-doctoral researcher David Patterson, ... of the Center for Free-Electron Laser Science (CFEL) in ... microwave fields to identify molecular variants apart, and to ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
... and researchers at John Theurer Cancer Center at HackensackUMC, one ... latest findings in blood-cancer research at the 2012 American Society ... 1-5. Their involvement in these studies is part of John ... "We are proud to make a contribution ...
... According to a new study, children exposed to ... at increased risk for chromosomal aberrations (CAs), which have ... a potentially more harmful and long-lasting subtype of CAs. ... Health (CCCEH) at the Mailman School of Public Health, ...
... Therapeutics Centre (ETC) under the Agency for Science and Technology ... has enabled the successful development of the most comprehensive and ... this highly advanced kit, doctors can now rapidly detect all ... with almost 100% accuracy, within a few hours. This is ...
Cached Biology News:John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting 2Children exposed to the common pollutant naphthalene show signs of chromosomal damage 2Children exposed to the common pollutant naphthalene show signs of chromosomal damage 3Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 2Made-in-Singapore H5N1 diagnostic kit -- detects all known strains of H5N1 virus with a single test 3
... --- a cocktail of 3 siRNAs specifically ... our most popular product. The siTrio reagent ... of your target gene when used under ... and confirmation of optimal transfection with one ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
Biology Products: